Trade Mark Journal No.2025/044 31 October 2025

UK00004180197 27 March 2025 (5,42)

HARNESSING NEXT-GENERATION SIRNA ENGINEERING

International priority date claimed: 7 October 2024 (United States of America) (98789220)

Class 5: Pharmaceutical preparations; Pharmaceutical preparations, including nucleic acid therapeutics for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys.
Class 42: Scientific research; Scientific research in the fields of pharmaceuticals and medicine; Providing scientific information in the field of pharmaceuticals and medicine; Product development for others in the field of pharmaceuticals and medicine.

City Therapeutics, Inc.

Representative: Howard Kennedy LLP